|US: Eli Lilly settles Zyprexa inquiries in 32 states|
by TOM MURPHY and MARLEY SEAMAN, Associated Press
October 7th, 2008
Drugmaker Eli Lilly & Co. cleared another legal cloud hanging over its top-selling drug Zyprexa when it announced a $62 million settlement Tuesday, but several other storms are still brewing for the antipsychotic medication.
|ARGENTINA: Is GlaxoSmithKline Behaving Badly in Argentina?
by AINA HUNTER, ABC News
September 23rd, 2008
Michaela, a deceased 5 month old, is one of more than 13,000 Argentine children to participate in a clinical study implemented a little more than a year ago by the London-based GlaxoSmithKline, the world's second-largest drug manufacturer.
|US: Judge to Unseal Documents on the Eli Lilly Drug Zyprexa
by MARY WILLIAMS WALSH, The New York Times
September 5th, 2008
A federal judge in Brooklyn decided on Friday to unseal confidential materials about Eli Lilly’s top-selling antipsychotic drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses.
|US: Altria Said to Be in Talks With Tobacco Maker UST
by ANDREW ROSS SORKIN and ANDREW MARTIN, The New York Times
September 4th, 2008
Altria Group is in advanced talks to buy UST, the maker of the popular Skoal and Copenhagen smokeless tobacco brands, for more than $10 billion, people with close knowledge of the negotiations said late Thursday. The terms could not be learned.
|US: U.S. Drug Ads Questioned
by KEITH J. WINSTEIN and SUZANNE VRANICA, The Wall Street Journal
September 3rd, 2008
Consumer advertising for prescription drugs had a negligible impact on sales of products studied by Harvard Medical School researchers -- in a finding that may confound both advertisers and their opponents.
|US: For Widely Used Drug, Question of Usefulness Is Still Lingering
by ALEX BERENSON, The New York Times
September 1st, 2008
About the only point on which both sides agree is that no one can judge ezetimibe’s safety and benefits for certain without more data, ideally from a clinical trial covering more than 10,000 patients and lasting several years, long enough to show that the drug actually helps patients live longer or avoid heart attacks.
|US: Files Show Governor Intervened With Court|
by Ian Urbina, New York Times
August 13th, 2008
West Virginia Governor Joe Manchin III filed a friend-of-the-court brief in June, arguing the State Supreme Court should review a $382 million judgment against DuPont. The case involves thousands of residents in the area of a DuPont-operated zinc-smelting plant, and the largest civil penalty ever levied against the company, for the dumping of toxic arsenic, cadmium and lead at the plant.
|US: WellCare to Restate Years of Results
by THEO FRANCIS, The Wall Street Journal
July 22nd, 2008
By accounting for medical expenses improperly, the company said it failed to return about $46.5 million in premiums to state programs providing health care to low-income adults and children in Florida and Illinois, and understated liabilities by about $46 million.
|US: Menthol Dose Manipulated, Study Says|
by STEPHANIE SAUL, The New York Times
July 17th, 2008
A new Harvard study claims that the tobacco industry in recent years has manipulated menthol levels in cigarettes to hook youngsters and maintain loyalty among smoking adults. The report could further inflame a controversy over menthol in pending tobacco legislation.
|INDIA: Decades Later, Toxic Sludge Torments Bhopal|
by Somini Sengupta, New York Times
July 7th, 2008
Residents of Bhopal, India continue to suffer from Union Carbide's toxic legacy, this time in the form of toxic waste that still languishes inside a shoddy warehouse on the old factory grounds. Ailments such as cleft palates and mental retardation are appearing in numbers of Bhopali children, raising questions about contaminated soil and groundwater, clean-up, and liability.
|US: Mannatech Settles Holder Suits
by SUZANNE SATALINE, Wall Street Journal
June 13th, 2008
Dietary-supplements maker Mannatech Inc. said it settled several lawsuits with shareholders who accused the company of using improper sales tactics to boost the value of the stock.